Time & Date: 3 September, 15:00 – 16:00 CEST
Moderator: P. Lanzetta ITALY
Speakers & Presentations:
P. Lanzetta ITALY
15:00 Welcome
J-F. Korobelnik FRANCE
15:02 A global non-interventional study of real-world proactive regimens with intravitreal aflibercept in patients with nAMD: XTEND study Year 1 primary analysis
A. Loewenstein ISRAEL
15:07 Global perspectives of patients and healthcare professionals on the challenges of managing nAMD in clinical practice: An interim analysis
S. Schmitz-Valckenberg USA
15:12 Quantification of Lesion Progression of Incomplete and Complete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration.
P. Lanzetta ITALY
15:17 Evaluation of 8 mg intravitreal aflibercept for neovascular age-related macular degeneration: Results from the Phase 2 CANDELA study
C. Delcourt FRANCE
15:22 Age-related macular degeneration and loss of autonomy : the Alienor-3C Study
J.M. Ruiz-Moreno SPAIN
15:27 Serum 25-hydroxy vitamin D levels in age-related macular degeneration.
C. Farinha PORTUGAL
15:32 Phenotypic expression of CFH rare variants in Age-related Macular Degeneration patients.
N. Eter GERMANY
15:37 Characterization of macular neovascularization subtypes in age-related macular degeneration to optimize treatment outcomes
R. Hogg UK
15:42 Monitoring for neovascular Age-related macular degeneration (AMD) Reactivation at Home: the MONARCH study
All Faculty
15:47 Discussion
